Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Tailoring Disease Screening Programs to Individuals

Published: Friday, March 21, 2014
Last Updated: Friday, March 21, 2014
Bookmark and Share
To address the current one size fits all approach a NSF-funded scientist has developed a computer algorithm that will allow women to reach a decision customized for them.

Oguzhan Alagoz believes that many existing disease screening programs all too often take a one-size-fits-all approach. To be sure, "it is important to catch a disease early," he says. "But still, most screening programs treat everyone the same."

In breast cancer, for example, "they say any woman who turns 40, or 50, should start screening every year, and they don't differentiate women by individual risks," says Alagoz, an associate professor of industrial and systems engineering at the University of Wisconsin-Madison.

"The common characteristic of all of these guidelines is age," he adds. "They specify age, but don't specify whether women with higher or lower risk should or should not be screened, nor do they take into consideration a woman's personal preferences about mammography. We have to start tailoring screening recommendations to the individual woman."

To try to address this, the National Science Foundation (NSF)-funded scientist has developed a computer algorithm that will allow women to reach a decision customized for them. "You enter your age, your risk factors and how you personally feeling about screening," he says. "Then our model helps you make a decision about mammography."

Although implementation is beyond the scope of his research, he believes the ideal scenario would be to have a woman use the computer model in consultation with her personal physician. "We shouldn't over-trust the model," says Alagoz, who also holds a secondary appointment as an associate professor of population sciences in the university's school of medicine and public health.

"Over-trusting technology in medicine may not be the best thing to do, but it will help you," he adds. "It also will help the physician and the women who might be missing certain things. I see this not as a method to guide the whole decision, but as a decision support tool."

Ultimately, he sees the research as a framework for developing better screening policies for other cancers as well, including prostate and colorectal cancers as well as other conditions, such as diabetic retinopathy.

"Any improvement on cancer screening and diagnosis would directly affect millions of people being screened for cancer, and indirectly affect almost the whole population being screened for other diseases," he says. "Furthermore, the potential life savings and dollar savings of the proposed research are substantial."

Alagoz is conducting his work with an NSF Faculty Early Career Development (CAREER) award, which he received in 2009 as part of the American Recovery and Reinvestment Act. The award supports junior faculty who exemplify the role of teacher-scholars through outstanding research, excellent education, and the integration of education and research within the context of the mission of their organization. NSF is funding his work with about $430,000 over five years.

As part of the grant's educational component, he is training doctoral students to use such operations research techniques to solve complicated decision problems in medicine, and plans to integrate his findings into new courses. "The research will introduce operations research tools to the medical community through a successful application of these tools to a complicated and controversial problem in medicine," he says.

He says there were a number of computational challenges he had to overcome in developing the model, and hopes to soon test it in a local clinic, although widespread clinical practice is likely several years away. "This is really very much still only on paper and in the computer," he says.

His description of the algorithm and how it works appeared in the journal Operations Research.

"Every model is a representation of a real life system," he says. "For this algorithm to work, we have to somehow represent the existence of cancer and probability of getting it over a lifetime."

For this, he used the so-called Markov decision process model, a popular operations research tool used in various areas of applications. His model only considers the present state--for example, the current condition of a patient--to predict the probability of a future state, in this case, the chances of a patient's developing cancer over a certain time period.

"There are already several risk assessment/predictions models that can tell you the probability of getting cancer over the next five or ten years, but this model also will consider your preferences and your risk and tell you at what age you should get a mammogram," Alagoz says. "Then it will tell you, if it is negative, you should get it at such and such an age. It makes a recommendation to you about when you should get your next mammogram and all kinds of other statistics."

The major difference between this model and other existing predictive algorithms "is that it takes into account how the woman feels about the procedure," he says, citing fears over mammography, the risk of false positives that could result in unnecessary biopsies and other tests. "We have to somehow translate your feelings into numbers, that is, how much quality of life is lost due to your feeling toward mammography, a false positive, a biopsy, and the possibility of breast cancer."

Alagoz hopes to include compliance as a factor in the next generation model. "What if she doesn't come back, how should we adjust our model to recommend more or less aggressive screening?" he says. "If compliance is very high, then less aggressive screening recommendations make more sense."

He also is using the model for investigating important screening policy questions such as what age to stop screening, what ages should be screened more aggressively, and the role of compliance in screening recommendations, among other things.

Alagoz is conducting his research with input from the medical community.

"The physicians are helping me build the models," he says. "When you build these models, you have to make some assumptions. I am not a physician, so I meet with physicians/epidemiologists every week who help me build the correct models."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antibacterial Properties of Clay Discovered
May be new answer to MRSA, other 'superbug' infections.
Monday, January 11, 2016
Scientific News
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos